132 related articles for article (PubMed ID: 12176645)
1. Low incidence of posttransplant lymphoproliferative disease in children treated with low-dose immunosuppression after liver transplantation.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
Transplant Proc; 2002 Aug; 34(5):1961-2. PubMed ID: 12176645
[No Abstract] [Full Text] [Related]
2. Neoral is superior to FK 506 in liver transplantation.
Levy GA
Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
[No Abstract] [Full Text] [Related]
3. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine.
Zajicek A; Esquivel C; Millan M; Cox K; Berquist R; Berquist W
Transplant Proc; 2002 Aug; 34(5):1976-8. PubMed ID: 12176653
[No Abstract] [Full Text] [Related]
4. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
Molmenti EP; Nagata D; Roden J; Squires R; Molmenti H; Casey D; Fasola C; Lopez MJ; Winick N; McPhail W; D'Amico L; Goldstein R; Levy M; Fasola C; Andersen J; Klintmalm G
Transplant Proc; 2001; 33(1-2):1727. PubMed ID: 11267487
[No Abstract] [Full Text] [Related]
5. Posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Uribe M; Hunter B; Alba A; Calabrán L; Flores L; Soto P; Herzog C
Transplant Proc; 2009; 41(6):2679-81. PubMed ID: 19716000
[TBL] [Abstract][Full Text] [Related]
6. Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder.
Walker RC
Transplant Proc; 1995 Oct; 27(5 Suppl 1):41. PubMed ID: 7482817
[No Abstract] [Full Text] [Related]
7. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
Kullberg-Lindh C; Saalman R; Olausson M; Herlenius G; Lindh M
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
Kamei H; Ito Y; Kawada J; Ogiso S; Onishi Y; Komagome M; Kurata N; Ogura Y
Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation.
Granot E; Doron D; Morag R
Transplant Proc; 2000 Jun; 32(4):706-7. PubMed ID: 10856551
[No Abstract] [Full Text] [Related]
10. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
11. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
[No Abstract] [Full Text] [Related]
13. Posttransplant lymphoproliferative disorders in adult kidney transplant recipients: clinical features and relationship to Epstein-Barr virus.
Lauzurica R; Bayés B; Frías C; Hernández A; Bonet J; Fontseré N; Jimenez A; Ausina V; Romero R
Transplant Proc; 2003 Aug; 35(5):1720-1. PubMed ID: 12962770
[No Abstract] [Full Text] [Related]
14. Outcome of PTLD in renal and liver allograft recipients.
Gerstenkorn C; Jackson G; Di Franco F; Thomusch O; Talbot D
Transplant Proc; 2001 Jun; 33(4):2469-72. PubMed ID: 11406215
[No Abstract] [Full Text] [Related]
15. Low rejection rate after hepatic transplantation achieved with a cyclosporine-based quadruple immunosuppressive regimen.
Ott R; Gralka S; Froschauer R; Born G; Müller V; Reck T; Hohenberger W; Köckerling F
Transplant Proc; 1998 Jun; 30(4):1427-9. PubMed ID: 9636578
[No Abstract] [Full Text] [Related]
16. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
Holmes RD; Orban-Eller K; Karrer FR; Rowe DT; Narkewicz MR; Sokol RJ
Transplantation; 2002 Aug; 74(3):367-72. PubMed ID: 12177616
[TBL] [Abstract][Full Text] [Related]
17. Optimal clinical regimens for living related liver transplantation.
Malagó M; Rogiers X; Wadström J; Burdelski M; Broelsch CE
Transplant Proc; 1994 Oct; 26(5):2665-8. PubMed ID: 7940834
[No Abstract] [Full Text] [Related]
18. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
19. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
[TBL] [Abstract][Full Text] [Related]
20. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
